Background: Allergen exposure chambers (AECs) are clinical facilities allowing for controlled exposure of subjects to allergens in an enclosed environment. AECs have contributed towards characterizing the pathophysiology of respiratory allergic diseases and the pharmacological properties of new therapies. In addition, they are complementary to and offer some advantages over traditional multicentre field trials for evaluation of novel therapeutics. To date, AEC studies conducted have been monocentric and have followed protocols unique to each centre. Because there are technical differences among AECs, it may be necessary to define parameters to standardize the AECs so that studies may be extrapolated for driving basic immunological research and for marketing authorization purposes by regulatory authorities. Methods: For this task force initiative of the European Academy of Allergy and Clinical Immunology (EAACI), experts from academia and regulatory agencies
met with chamber operators to list technical, clinical and regulatory unmet needs as well as the prerequisites for clinical validation. Results: The latter covered the validation process, standardization of challenges and outcomes, intra-and interchamber variability and reproducibility, in addition to comparability with field trials and specifics of paediatric trials and regulatory issues. Conclusion: This EAACI Position Paper aims to harmonize current concepts in AECs and to project unmet needs with the intent to enhance progress towards use of these facilities in determining safety and efficacy of new therapeutics in the future.
Environmental exposure chambers (EECs) have been developed to generate controlled exposures to inhaled substances such as allergens, endotoxins, chemicals, dry/ humid air, thermal shifts or air pollutants. Some of these EECs are used exclusively for controlled exposure of environmental allergens to subjects with allergic rhinitis, conjunctivitis or asthma. The number of these allergen exposure chambers (AECs) available worldwide is limited because of their technological complexity, and the intricacies of the experimental protocols necessary to perform a valid study.
However, during the last 4 years the number of AECs, as well as the number of clinical trials using AECs, has increased (1). Meanwhile, European regulatory authorities have shown interest in assessing the broader utility of AECs in drug development, specifically for allergen immunotherapy (AIT), based on well-defined criteria and protocols/procedures (2) .
In addition, AECs have contributed towards understanding the pathophysiology of allergic rhinitis, local (nonsystemic) allergic rhinitis, allergic conjunctivitis, allergic asthma and of the pharmacological properties, efficacy, and onset/duration of action of new therapeutics (1, 3, 4) . Because subjects are exposed to defined levels of allergens for a specific length of time, AECs may complement traditional multicentre field trials. As the frequency of mechanistic and therapeutic trials in AECs has increased, it has become apparent that defining characteristics of each AEC in a standardized manner, and harmonizing protocols for these studies will improve the quality of data acquired in all chamber facilities and may allow for better application towards proving the safety and efficacy of novel therapeutics. Therefore, this EAACI Position Paper aims to outline the most relevant unmet needs and prerequisites for validation of current and future AECs.
Materials and methods

Aims of the task force
Our first aim was to gather precise information from the AEC operators to understand the specifications of each AEC, including their similarities and differences, and potential future improvements. We also aimed to define minimal criteria to perform an acceptable study, including allergen sources, and airborne concentration of the allergens, including spatial and temporal uniformity, and distribution in particle size.
This information will serve towards (i) defining procedures that will lead to well-defined and reproducible allergen exposures; (ii) establishing maximum safety for the subjects, particularly those with asthma; and (iii) defining procedures to aid manufacturers of therapeutics to choose the most adequate challenge method to support regulatory requirements for approval.
Invited participants
To define the role of AECs in the development of new interventions and to give the most suitable recommendations, we followed EAACI standard procedures for running task forces, and invited all European and North American groups working with chamber facilities as well as representatives of regulatory authorities to participate in this project.
Consultation procedure
Direct contacts were initiated by emails. We then made a list of available AECs worldwide (Table 1) . After open discussion, we focused on two specific issues: (i) (most relevant) unmet needs for the future and (ii) prerequisites for the clinical validation of AECs currently in use.
Participants were given 3 months to write their views, which were then compiled in a comprehensive draft (Pfaar/ Demoly/Calderon) and sent for further email discussion, tuning and approval. The final manuscript was approved by EAACI ExCom before submission.
What are the (most relevant) unmet needs in the future of AECs?
Validation process
The task force committee understands the purpose of AECs as a technology in which the allergen exposure is controlled, stable and independent from the season or weather conditions or any other random external physical and environmental factors. AECs contribute towards drug development for upper and lower airway hypersensitivity/allergic diseases and mechanisms to characterize the pathology and natural history of allergic disease, develop subject reporting tools and to validate patient-reported outcomes. Because AECs decrease variability of exposure, the number of subjects required to test a therapeutic or mechanistic hypothesis may be lower than for a standard field trial. In addition, because the exposures occur over a defined period of time, the overall length of each study is much shorter than in field trials. Since the performance of valid trials is dependent on the technology of AEC, the validation process should be harmonized and transparent for every AEC. Without validation and harmonization, it may be difficult to extrapolate from a trial performed in one AEC towards another, and from any AEC trial to field studies.
This process should include the following: (i) The validation for each allergen used because airborne characteristics may vary among allergens. All factors that may impact on upper and lower airway allergy should be controlled and adapted on demand to consider the following criteria: Continuous registration of airborne allergen concentration per m 3 air with the coefficient of variation, 
Standardization of the challenge procedures and assessments
The challenge procedures and assessments should be standardized with recommendations on how to perform them according to the objective(s) of the study: 1 Duration of exposure and read-out: Duration of exposure may vary according to the study objectives (2, 4, or even more hours, on one or several consecutive days). A stable plateau of symptoms should be reached. The respective read-out should be justified and harmonized. 2 Single-vs-serial (daily) challenges: Priming in allergic patients occurs in real life (12) and attempts to reproduce this in chambers are published in studies of serial exposure in an AEC to Juniperus pollen (9), house dust mites (7) and cat allergens (13) . Therefore, single-vs-serial challenge procedures must be justified according to study Box 1: Regarding the validation process of allergen chambers, the group recommends 1 A validation of the allergenic exposure, including at least pollen grain counts and distribution 2 The use of GMP-grade allergens when processed material is mandated by local regulatory agencies 3 Control of the chamber environment 4 Standard operating procedures for cleaning of the facilities after each exposure 5 Standard operating procedures for chamber operation including data collection/management 6 Logging of the above data for each exposure session objective(s) and in particular, with respect to the intervals between serial challenges and to the potential impact of allergy seasons to the patient's responsiveness to a controlled allergen challenge in the AEC. 3 Allergen exposure level: The purpose of AEC is to expose subjects to levels of allergens that are stable and reproducible. Some investigators try to induce a symptom severity level comparable to that documented in real life. However, comparisons of symptom severity between natural seasonal and chamber exposure to three major pollens revealed that natural seasonal symptoms were more severe due to cofactors (14) . Other investigators try to induce maximum levels of symptom severity in all patients. Therefore, low-vs high-dose challenge procedures must be justified according to study objective(s) and potential ethical issues. 4 Justification of patient selection and screening should be reported, including specific inclusion and exclusion criteria, and study stopping criteria based on severity of symptoms and in line with the study protocol. 5 All outcome measures in AEC studies should be clinically relevant and standardized. a Standardized procedures for symptom scoring should be delineated along with standardized instructions for subjects on how to score. The symptom medication score is the primary outcome for field trials that has been determined by consensus in an EAACI Position Paper (15) . Because concomitant anti-allergic medications are not allowed during AEC studies, the most obvious primary outcome for AEC studies is the symptom score on a 0-3 scale [e.g., using the four nasal symptoms' score and if deemed useful according to the allergen employed and the respective protocol, ocular and bronchial symptoms' score (2, 16)] b Timing to assess the outcomes for each allergen extract should also be reported. Previous studies of allergen challenges of either grass pollen or HDM show that symptom scores rise over the first 1-2 h and are followed by a plateau phase. The plateau phase indicates that the symptom scores have stabilized, and was therefore considered the more relevant time to analyse the primary outcome (13, (17) (18) (19) . c Along with the evaluation period, the calculation of the effect size (e.g., mean and/or AUC) should be reported and justified in the study protocol prior to performance of the study and data analysis. 6 Chamber-specific placebo (development of symptoms in sensitized patients exposed to allergen-free air, the socalled 'sham run') and nocebo (development of symptoms due to just seeing chamber subjects with exacerbation of allergic symptoms) effects should be documented as it increases the validity of the exposure tests. 7 Safety measures should be specified in terms of:
a Selection of subjects suitable for exposure, b Prevention of adverse reactions (e.g., by monitoring symptoms and lung function in asthmatic patients),
c Availability of emergency medical personnel and resuscitation equipment, d Availability of nearby emergency room and intensive care facilities, e Definition of surveillance procedure following exposure (e.g., late-phase asthmatic reaction), f Reporting of all adverse events and their treatment.
Intra-AEC reproducibility
Reproducibility of findings among studies in the same chamber is a critical consideration towards advancing use of AEC. If conditions are tightly controlled, repetition of the same protocol on separate occasions should yield the same results. This reproducibility has been reported with the Vienna Challenge Chamber (VCC) (Vienna, Austria), the EEC (Mississauga, Canada), the Environmental Exposure Unit (EEU) (Kingston, Canada), the Chamber at Department of Public Health, Aarhus University (Aarhus, Denmark), Biogenics Research Chamber LLC (San Antonio, TX, USA), Mobile Chamber Experts (MCX) (Berlin, Germany) and the Fraunhofer Allergen Challenge Chamber (Hannover, Germany) (7, (20) (21) (22) (23) (24) (25) (26) . Other facilities should publish their reproducibility data.
Inter-AEC variability and reproducibility
Studies conducted to date have been monocentric, and there are technical differences between units, the most palpable being the method of allergen dispersion and the method of monitoring allergen concentration (27) (28) (29) . It is unclear at present how outcome measures compare between units when identical protocols are used (variability) and how outcomes compare when the same subjects are challenged at different units (reproducibility). Regulatory authorities and other stakeholders would have greater confidence in clinical efficacy (such as pivotal phase 3) studies conducted in multiple AECs across multiple countries once a common standardized protocol and clinical outcomes in one facility are comparable to those in another facility.
Comparability with field trials
One major issue is the comparability of AEC data with data obtained in field trials. For AEC studies, exposure
Reporting and justification of the calculation of the effect size of the intervention 7 Definition of safety measures parameters are precisely defined and reproducible, but for natural exposure they are not. To determine comparability, it would be necessary to sufficiently quantify the natural allergen exposure at the individual level for each subject, which is currently not possible. Regulators and other stakeholders would appreciate data supporting the fact that treatment effects are equal when studied in an AEC compared with a traditional field trial, while the magnitude of measured effects may differ. The solution may be combined studies evaluating subjects in real life, for example pollen season, with additional embedded challenge sessions (2). To date, there is a paucity of hybrid trials where the same intervention is investigated 'in the field' as well as in an AEC exposure for direct comparability in the same subject population (8) . Simple comparisons of treatment effect sizes between AEC and field trials are not entirely scientifically correct for several reasons. Rescue medications are allowed in the latter but not in the former, and allergen exposure is controlled and quantified in the former but not in the latter. Another aspect is that in AEC trials subjects who develop symptoms at screening as part of fulfilling the inclusion criteria are enrolled, whereas in most cases field trials recruit subjects based only on their history and their sensitization profile.
Paediatric issues
Long-term paediatric, placebo-controlled field trials are difficult to perform and are often inconclusive because there are no objective efficacy parameters for allergenic therapeutics. Safely executed in 5-to 11-years-old children and 12-to 17-years-old adolescents, AEC challenges may hasten development of therapeutics for children and may provide a major step towards changing the required criteria of the Paediatric Investigation Plan (PIP) of the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) or other regulatory agencies (30, 31) . Ideally, clinical validation should be done during a short-term efficacy and safety field trial, followed by AEC studies for long-term efficacy in children. For very young subjects, consideration should be given to symptom scoring by an accompanying parent.
Regulatory issues
In 2013, American Academy of Allergy, Asthma & Immunology (AAAAI) and EAACI PRACTALL experts (32) for the first time advocated for validation and acceptance of AEC as suitable surrogates for natural allergen exposure for the study of allergic diseases. Clinical efficacy can be demonstrated for therapeutic agents with fewer subjects and within shorter timelines, meriting higher ethical ground than in traditional trials. An AEC study may even be an option for developing therapeutics for rare allergies, for example those which affect a smaller number of the population which are not developed due to the clinical requirements for a marketing authorization (33, 34) .
For dose-finding studies, EMA 2008 guidelines (2) state that 'provocation tests (. . . or allergen exposure in allergen challenge chambers) and/or clinical endpoints may be used as primary endpoints'. For confirmatory studies, 'provocation tests in allergen chambers (are) deemed to be a promising tool for the evaluation of efficacy, however the results of such provocations have to be validated in comparison with clinical symptoms by natural exposure'. For long-term studies, AEC 'might be a helpful marker', especially in case of low natural pollen counts (2) . Regulatory authorities will be interested in the confirmation of phase 3 field trial results in AEC studies (e.g., in 'hybrid' model as described above) although whether AEC studies are acceptable for pivotal efficacy trials may vary among the various regulatory bodies. However, such models would make a comparison of study results feasible and might support to update the EMA guideline (2) .
To do this, there are financial as well as technical issues (size of the investment and number of allergen chambers needed, respectively) that must be considered. This mostly concerns short-term studies, but AEC might also be useful to test sustained and long-term effects. Prerequisites for clinical validation should be developed.
What are the prerequisites for the clinical validation of AECs?
As outlined above, the validation of clinical trials performed in several chambers, spread in widely disparate geographic areas and using different engineering and technology, would be required to address all the above unmet needs. The prerequisites therefore include definition and standardization (i) of technical parameters as described above and (ii) of clinical SOPs, definition of meaningful and valid clinical and statistical parameters, and reproducible dose response in clinical symptoms. Validation utilizing a standardized protocol demonstrating reproducibility and consistency of results between competing chambers must be accomplished.
Box 3:
Regarding comparability of allergen chamber trials with field trials, the group recommends that 1 Direct comparison is not possible (as natural allergen exposure cannot be determined and rescue medication is allowed in field trials) 2 Indirect comparison of effect sizes is possible when allergic subjects with comparable clinical characteristics are evaluated 3 Hybrid designs are feasible and may be an option Box 4: Regarding regulatory issues for allergen chambers, the group recommends that 1 If the above (Boxes 1-3) issues are solved, AECs can be used not only for phases 1 and 2 but also for confirmatory phase 3 trials. 2 We all agree on the prerequisites listed below for the clinical validation of AECs.
Regarding AIT, AEC models have demonstrated to be useful in establishing the maximum effect size without concomitant rescue medication (35, 36) , the onset of action (35, 36) , the long-term treatment effects (37) and, possibly, the validation of new clinical outcomes (3) and biological markers (38, 39) .
Presently, it cannot be predicted which outcomes have to be obtained in order to claim chamber trials as being valid and complementary for marketing authorization. Thus, it should be documented in detail, to what extent the efficacy of an investigational medicinal product (IMP) shown in an AEC setting can predict efficacy during a season or a chronic exposure to a perennial allergen source. To this end, the following two questions will have to be answered: (i) what is the effect size of a therapeutic intervention such as AIT in an AEC trial, (ii) what is the relationship between the effect size in an AEC and that in a field trial (where allergen exposure vary and symptom-relieving medication is permitted)? The kinetics of increase in symptom scores should be determined for each AEC and each allergen source to determine the plateau of symptoms. A thorough discussion and consensus on protocol standardization and/or SOPs for the evaluation of symptom scores in the AEC should be promoted. Other metrics of meaningful clinical outcomes [such as minimal clinically important difference (MCID), numbers needed to treat (NNT)] can be used.
Conclusion
If all AEC operators collaborate and address the issues outlined in this document, the group is confident that chamber studies will rank highly in product development for allergic diseases and in the decisions taken by regulatory authorities with respect to marketing authorizations.
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